Novo Nordisk Pharmatech enters important distribution agreement with Azelis for pharmaceutical grade quaternary ammonium compounds


Novo Nordisk Pharmatech enters important distribution agreement with Azelis for pharmaceutical grade quaternary ammonium compounds


Novo Nordisk Logo

Press Release | Novo Nordisk Pharmatech A/S

MAY 30, 2017

Koege, Denmark & Antwerp, Belgium: – Novo Nordisk Pharmatech A/S has entered into an agreement with Azelis for the distribution of pharmaceutical grade quaternary ammonium compounds (quats) to the pharmaceutical and medical device markets in Germany, Spain Portugal, UK and Ireland.

Matthew Dickman, Market Segment Director Pharma Azelis explains: “Novo Nordisk Pharmatech is the industry leader in pharmaceutical grade quats and we are delighted they have chosen Azelis Pharma as their distribution partner for the development of these markets. Novo Nordisk Pharmatech’s quats complement an existing Azelis portfolio of pharma antimicrobials. Alongside established uses of quats, our Pharma experts see potential new applications in the growing wound care market. Our local teams, who work with customers to support both their current and NPD requirements, will be investigating these options in the coming period.”

Novo Nordisk Pharmatech manufactures its quats (Benzalkonium, Cetrimide and Cetyl Trimethyl Ammonium Bromide, including customised grades) to the highest (c)GMP standards. Their site (Koge/Denmark) is audited by the Danish Medicines Agency and US-FDA. Products comply with the latest major pharmacopoeia and are supported by CEPs, DMFs and a comprehensive package of regulatory and quality assurance documents.

“We are very happy to work with Azelis as our distribution partner for pharmaceuticals. Novo Nordisk Pharmatech’s FeF™Quats products fit perfectly with Azelis existing antimicrobial portfolio enabling the customers to take advantage of these synergies. We wish to give the best service to our customers and the local pharma teams of Azelis are experts in working with customers to support their current and product development requirements.” says Steve Profit, Sales & Marketing Director at Novo Nordisk Pharmatech A/S.

About Novo Nordisk Pharmatech A/S

Novo Nordisk Pharmatech A/S was established in 1949 as FeF Chemicals, acquired by Novo Nordisk in 1986 and has been part of the pharmaceutical group since then. On 1 September 2015 the company’s name was changed to Novo Nordisk Pharmatech A/S. It is the leading worldwide supplier of recombinant insulin for cell growth media and pharmaceutical grade quaternary ammonium compounds (Quats) for the pharmaceutical, biopharmaceutical and personal care industries.

The company markets its diabetic care, hemophilia, growth hormone therapy, obesity, and hormone replacement therapy (HRT) products worldwide, with customers in more than 180 countries.

All Novo Nordisk Pharmatech products are manufactured to cGMP standards. The company has distinguished itself for global regulatory compliance, consistent high quality, extensive regulatory documentation, continuous availability, security of its global supply chain and high levels of service and support.

For Financial Year 2015, Novo Nordisk reported world sales totaling 107,927 million Danish kroner (DEK) with more than half of all sales recorded in North America.

About Azelis

Azelis is the leading global speciality chemicals distributor providing a diverse range of innovative products and services. Dedicated teams serve customers in the following industries: Personal Care, Pharma, Food & Health, Animal Nutrition, Specialty Agri/Horti, Homecare & Industrial Cleaning, CASE (coatings, adhesives, sealants, elastomers) Chemicals, Lubricants & Metal Working Fluids and Rubber & Plastic Additives. Through sourcing and distribution channels in every major market around the world, Azelis with its corporate service centre in Antwerp, Belgium, offers chemical producers market penetration, in-depth local knowledge, value-added services and tailored multi-territory solutions. Azelis has a turnover of ca. €1.5 billion and employs around 1,500 knowledgeable people located in more than 45 facilities in over 35 countries across the EMEA, Asia Pacific and Americas regions.

Media Contact

Vanessa León, Marketing Manager, Novo Nordisk Pharmatech A/S
Tel:+45 404 262 84
Email: vnlt@novonordiskpharmatech.com

Resources

Click on Novo Nordisk Pharmatech enters agreement with Azelis for more information.
Click on Novo Nordisk Pharmatech to contact the company directly.


Supplier Information
Supplier: Novo Nordisk Pharmatech A/S
Address: Koebehavnsvej 216, 4600 Koege, Denmark
Tel: +45 566 71000
Fax: + 33 38 331 2483
Website: http://novonordiskpharmatech.com/


Comments are closed.